# A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

> **NCT01516047** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 16 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Cohort 1
- **DRUG:** Cohort 2

## Key facts

- **NCT ID:** NCT01516047
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516047, "A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01516047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*